Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Inclusion Criteria:

• Age > 18 years - male or female

1. Eligible female non-pregnant participants who are either not of child-bearingpotential or willing to utilize adequate contraception during the trial

2. Males must be willing to practice abstinence or utilize adequate contraceptionfrom MB-102 dosing day to at least 7 days post dose

• Participants willing to comply with study requirements

• Participants who have signed an informed consent form

At least 5 participants will have a current history of retinal or choroidal vascular diseases.

Exclusion Criteria:

• Women who are pregnant, lactating or planning to become pregnant during the study,or women who are of childbearing potential unwilling to utilize adequatecontraception

• Participation in another interventional trial within 30 days of treatment orconcurrently enrolled in any other medical research study which could impact theresults of the study

• History of drug or alcohol abuse within the past year

• History of severe allergic hypersensitivity reactions (unacceptable adverse events)or anaphylactoid reaction to any allergen including drugs, MB-102 and fluoresceinsodium or other related products (intolerance to a drug is not considered a drugallergy).

• Prior history of seizures

• Current visually significant cataracts or other ophthalmic conditions that wouldlimit appropriate collection of fundus photographs

• Site personnel immediately associated with the study or their immediate familymembers

• Unable to tolerate ophthalmologic imaging

• Any characteristics which, in the opinion of the investigator, makes the participanta poor candidate for participation in the clinical trial (e.g. unstable medicalcondition including cardiovascular disease, or other conditions consideredclinically significant or unstable by the Principal Investigator)

• Prior enrollment and dosing in this study